Cocozzella Daniel, Curciarello José, Corallini Osvaldo, Olivera Adriana, Alburquerque María Malca, Fraquelli Emilio, Zamagna Liliana, Olenchuck Alejandro, Cremona Alberto
Gastroenterology Service (Liver Unit), National University Medical School at La Plata, Hospital Rodolfo Rossi, La Plata, Argentina.
Dig Dis Sci. 2003 Feb;48(2):354-7. doi: 10.1023/a:1021943930424.
Two patients developed acute cholestatic hepatitis during treatment with propafenone. Viral infections, alcohol abuse, hepatotoxicity by other drugs, and biliary obstruction were excluded as causes. In one patient, liver biopsy showed changes consistent with a drug-associated injury. Another patient had autoimmune antibodies (ANA) in the serum. Following propafenone withdrawal, the clinical and biochemical profiles of both patients improved. Hepatic toxicity from the antiarrhythmic drug propafenone is highly uncommon. Moreover, the drug produces hepatocellular injury by an unknown mechanism. Most of the seven cases reported here had acute cholestatic hepatitis after a latency period of two to four weeks.
两名患者在使用普罗帕酮治疗期间发生急性胆汁淤积性肝炎。排除了病毒感染、酒精滥用、其他药物的肝毒性和胆道梗阻等病因。其中一名患者的肝活检显示出与药物相关损伤一致的变化。另一名患者血清中有自身免疫抗体（抗核抗体）。停用普罗帕酮后，两名患者的临床和生化指标均有所改善。抗心律失常药物普罗帕酮引起的肝毒性非常罕见。此外，该药物通过未知机制导致肝细胞损伤。此处报告的7例病例中，大多数在2至4周的潜伏期后发生急性胆汁淤积性肝炎。
Zotero 插件